Filtered By:
Condition: Peripheral Vascular Disease (PVD)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2060 results found since Jan 2013.

Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary
Biomed Environ Sci. 2023 Aug 20;36(8):669-701. doi: 10.3967/bes2023.106.ABSTRACTIn the past 30 years, the accessibility and quality index of medical care have made remarkable progress in China, ranking the first among middle-income countries. Many cardiovascular technologies are at or near the world's leading level, and significant progress has been achieved in China solving the problem of "treatment difficulty" of cardiovascular diseases (CVD). However, due to the prevalence of unhealthy lifestyles among Chinese residents, a huge population with CVD risk factors, accelerated population aging, and other reasons, the incide...
Source: Biomedical and Environmental Sciences : BES - September 15, 2023 Category: Biomedical Science Authors: Writing Committee Of The Report On Cardiovascular Health And Diseases In China The Source Type: research

Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary healthcare in Catalonia
Conclusion: Being men, a previous event and DOAC-switch posed a higher risk for all study outcomes. direct oral anticoagulants had a protective effect against cerebral bleeding in comparison to vitamin K antagonists. Adherence to direct oral anticoagulants resulted in lower risk of stroke and cerebral bleeding. We found no differences in the risk of stroke and gastrointestinal bleeding when we compared direct oral anticoagulants vs. vitamin K antagonists.
Source: Frontiers in Pharmacology - September 15, 2023 Category: Drugs & Pharmacology Source Type: research

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news

Association between within-visit blood pressure variability, stroke, coronary heart disease, and cardiovascular mortality
CONCLUSIONS: Within-visit variability in SBP is associated with increased risks of stroke, coronary heart disease, and cardiovascular mortality, but the relationship is confounded by age and covariates.PMID:37655640 | DOI:10.5603/pjnns.94839
Source: Neurologia i Neurochirurgia Polska - September 1, 2023 Category: Neurology Authors: Bhrugun Anisetti Hossam Youssef Ahamed M Elkhair Michelle P Lin Source Type: research

In-stent restenosis after vertebral artery origin stenosis stenting: a nomogram for risk assessment
Conclusions A nomogram and a risk evaluation table were developed with good predictive ability for in-stent restenosis among patients with VAOS, which could serve as a practical approach for individualized risk evaluation.
Source: Journal of NeuroInterventional Surgery - August 29, 2023 Category: Neurosurgery Authors: Yang, K., Fang, S., Zhang, X., Wang, T., Feng, Y., Jiao, L., Yan, Y. Tags: Ischemic stroke Source Type: research

Cardiovascular and renal health: Preeclampsia as a risk marker
CONCLUSIONS: The implementation of preventive multidisciplinary targeted strategies can help slow down CVD and CKD's natural history in women at risk through lifestyle modifications and adequate blood pressure control. Therefore, we propose a series of recommendations to guide the prediction and prevention of CVD and CKD throughout life of women with a history of PE.PMID:37635012 | DOI:10.1016/j.nefroe.2022.04.009
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - August 27, 2023 Category: Urology & Nephrology Authors: Cecilia Villala ín González Ignacio Herraiz Garc ía Leticia Fern ández-Friera Gema Ruiz-Hurtado Enrique Morales Jorge Sol ís Alberto Galindo Source Type: research